Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker studyAziz Zaanan, Pierre Laurent‐Puig, Antoine Mariani et al.|Nature Communications|2025Cited by 25
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational OpportunitiesAnne Knisely, Amir A. Jazaeri, Yibo Dai et al.|Clinical Cancer Research|2025Cited by 10
Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ADENOCA): The PLAGAST prospective biomarker study.Aziz Zaanan, Pierre Laurent‐Puig, Audrey Didelot et al.|Journal of Clinical Oncology|2024Cited by 5
Prognostic implications of minimal residual disease detection by second-look laparoscopy and circulating tumor DNA among patients with ovarian cancer after front-line therapyAnne Knisely, Amir A. Jazaeri, Sanghoon Lee et al.|Gynecologic Oncology|2024Cited by 1